Alaunos Therapeutics, Inc. TCRT
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -50.77%
- 1 year
- -51.96%
- Market cap
- 6.69M
- Revenue (ttm)
- 7.00K
- EPS (ttm)
- -1.76
- Shares out
- 1.60M
- Forward P/E
- -3.25
- YTD return
- -50.77%
- 1-year return
- -51.96%
- Volume
- 91.01K
- Avg volume
- 7.55M
- Open
- 1.67
- Previous close
- 1.71
- Day's range
- 1.56 – 1.70
- 52-week range
- 0.72 – 4.50
- Beta
- -0.50
Key statistics
- 50-day average
- 2.18
- 200-day average
- 6.90
- Enterprise value
- 883.62K
- Price / sales
- 446.15
- Price / book
- 0.50
- Free cash flow
- -11.83M
- Total cash
- 2.46M
- Return on equity
- -150.50%
- Short % of float
- 10.11%
Fundamental scorecard
7 of 25 checks passed on TCRT’s reported financials
7of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.70 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.71 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -1.10 | — | — |
| Apr 2, 2024 | Dec 1, 2023 | -0.60 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -4.50 | -6.00 | -1.50 | -33.33% |
| Aug 14, 2023 | Jun 1, 2023 | -6.00 | -6.00 | 0.00 | 0.00% |
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alaunos.com
News
Alaunos Therapeutics, Inc. (TCRT) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
Your note
Sign in to keep a note on TCRT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAFFA RAFFAELE | Officer | Stock Award(Grant) | May 16, 2021 | 280,645 |
| BOWDEN CHRISTOPHER J | Director | Stock Award(Grant) | Jun 21, 2022 | 44,167 |
| BOYLE KEVIN S. SR | Chief Executive Officer | Sale | Aug 31, 2023 | 798,236 |
| DE GROOT ELEANOR M | Officer | Sale | Dec 21, 2021 | 237,106 |
| HAGEN HEIDI | Director | Purchase | Sep 1, 2021 | 145,889 |
| HUANG JAMES Z | Director | Stock Award(Grant) | Jun 21, 2022 | 188,333 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MSD Partners, L.P. | 6.31% | 101,010 | 197.01K | Sep 29, 2024 |
| Vanguard Group Inc | 2.83% | 45,348 | 88.45K | Sep 29, 2024 |
| Blackrock Inc. | 1.39% | 22,233 | 43.36K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.02% | 16,333 | 31.86K | Sep 29, 2024 |
| Morgan Stanley | 0.08% | 1,337 | 2.61K | Sep 29, 2024 |
| UBS Group AG | 0.06% | 1,028 | 2.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.60% | 25,676 | 50.08K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.28% | 20,471 | 39.93K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 8,924 | 17.41K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 2,376 | 4.63K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 2,082 | 4.06K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Core Equity 2 ETF | 0.08% | 1,271 | 2.48K | Jul 30, 2024 |
